In vivo studies of gene expression via transient transgenesis using lipid-DNA delivery.
As the sequencing of the human genome proceeds, the need for a new screen for in vivo function is becoming apparent. Many investigators are turning to various transgenic models as a means of studying function. However, these approaches are very time consuming, with a transgene-expressing mouse model often taking months to establish. We have developed an efficient system for delivering genes in vivo, which allows the gene product to be studied as early as 24 h after introduction into the mouse model. The delivery system employs a novel cationic lipid, 1-[2-(9-(Z)-octadecenoyloxy)ethyl]-2-(8-(Z)-heptadecenyl)-3- (hydroxyethyl)imidazolinium chloride (DOTIM), and a neutral lipid, cholesterol, complexed with an expression vector containing the reporter gene chloramphenicol acetyl transferase (CAT). After a single intravenous injection of these complexes, several tissues were seen to express the transgene. High, persistent expression in the vascular endothelial cells in the mouse lung was obtained. Delivery of DNA in vivo has been evaluated by quantitative polymerase chain reaction and protein expression by CAT activity assays. In vivo studies showed reproducible expression in more than 500 mice injected via the tail vein. An early peak of expression was followed by lower, but sustained, expression for > 50 days. Transgene expression of CAT could also be identified by immunohistochemistry staining in mouse lung and appeared to be located within the capillaries. The pattern of in vivo expression could be modulated and targeted to specific organs by altering the lipid-DNA formulation. New expression vectors with altered introns and polyadenylation sites further improved expression. The expression reported here may be sufficient in magnitude, duration, and flexibility to be an attractive alternative, in some cases, to establishing transgenic animals by stable gene transfer.
McClarrinon
M
M
Valentis, Inc., Burlingame, California 94010, USA.
Gilkey
L
L
Watral
V
V
Fox
B
B
Bullock
C
C
Fradkin
L
L
Liggitt
D
D
Roche
L
L
Bussey
L B
LB
Fox
E
E
Gorman
C
C
D000818:Animals; D030801:Animals, Genetically Modified; D015500:Chloramphenicol O-Acetyltransferase / Q000032:analysis / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D015870:Gene Expression; D018390:Gene Targeting; D017930:Genes, Reporter; D005818:Genetic Engineering / Q000379:methods*; D005822:Genetic Vectors; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D007093:Imidazoles / Q000378:metabolism*; D050356:Lipid Metabolism; D008055:Lipids; D008168:Lung / Q000033:anatomy & histology / Q000378:metabolism; D051379:Mice; D010179:Pancreas / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013154:Spleen / Q000378:metabolism; D013997:Time Factors; D014162:Transfection / Q000379:methods*
C120715:1-(2-(9-octadecenoyloxy)ethyl)-2-(8-heptadecenyl)-3-(hydroxyethyl)imidazolinium; D007093:Imidazoles; D008055:Lipids; D016179:Granulocyte Colony-Stimulating Factor; D015500:Chloramphenicol O-Acetyltransferase